VCNX News and Press, Vaccinex Inc. From 08/16/21

Patients are currently being screened and enrolled in two studies of pepinemab as monotherapy in Alzheimer’s disease and in combination with KEYTRUDA ® in Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Ended the second quarter with cash and cash equival...

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Economic reports in the week ahead U.S. markets are only open for four trading days after taking a breather for the Independence Day holiday. It is a quiet...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

ROCHESTER, N.Y., June 30, 2021 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology Company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of SEMA4D, today announced that Elizabeth Evans, PhD, Chief O...

ROCHESTER, N.Y., June 08, 2021 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology Company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of SEMA4D, today announced that the first clinical sites have...

The following slide deck was published by Vaccinex, Inc. in conjunction with this event. For further details see: Vaccinex (VCNX) Presents At 2021 Global Healthcare Virtual Conference - Slideshow

ROCHESTER, N.Y., May 19, 2021 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the inhibition of SEMA4D, today announced that Dr. Maurice Zauderer, chief ex...

Initiated Phase 2 study of pepinemab in combination with KEYTRUDA® in advanced, recurrent or metastatic head and neck cancer Announced publication of results from CLASSICAL-Lung phase 1b/2 clinical trial in non-small cell lung cancer in the peer-reviewed journal Clinical ...

Brooklyn ImmunoTherapeutics (BTX) +38%.Regional Health Properties (RHE) +21%.Gaucho Group Holdings (VINO) +15%.Ashford Hospitality Trust (AHT) +15%.Ocugen (OCGN) +13% as COVAXIN demonstrated potential effectiveness against the Brazil variant of SARS-CoV-2, B.1.128.2.DAVIDsTEA (DTEA) +10%...

Vaccinex (VCNX) announces results from the its CLASSICAL-Lung clinical trial in the journal Clinical Cancer Research.The Phase 1b/2 trial evaluated pepinemab, in combination with the immune checkpoint inhibitor Bavencio (avelumab) for the treatment of non-small cell lung cancer ((NSCLC))...